I am a biostatistician specialising in Bayesian and early-phase trial methodology at UCB. I have experience in cancer and non-cancer clinical trials. I have authored several methodology papers and conducted the analysis for several trial results publications. By honourary association, I lead a MSc module on early phase trials at the University of Birmingham and supervise PhDs on trial methodology.
PhD in Clinical Trial Methodology, 2019
University of Birmingham
MSc in Statistics, 2011
University of Sheffield
BSc in Mathematics, 2001
University of London
We collected efficacy and toxicity outcomes from 122 published dose-finding trials. This project introduces the data and our insights.
escalation is an R package for dose-escalation clinical trials, providing a consistent, extensible, modular approach.
PePS2 is a phase II trial of pembrolizumab in performance status 2 non-small-cell lung cancer patients.
escalationfor TPI, mTPI and Neuenschwander et al.‘s design for phase I trials, plus MCMC-based CRM …
escalationpackage, how they work together, and how they will grow.
Therapeutic blockade of the axis of programmed cell death 1 (PD-1) and its ligand (PD-L1) has transformed the management of non-small-cell lung cancer (NSCLC). Clinical trials with pembrolizumab have enrolled patients with performance status (PS) 0–1. However, around 18% of patients with NSCLC are PS2, and the activity and safety of pembrolizumab in these patients is unclear. We aimed to evaluate the safety and efficacy of pembrolizumab in these patients.
This manuscript introduces an R package called trialr that implements a collection of clinical trial methods in Stan and R. In this article, we explore three methods in detail…
Another promotion at the Cancer Research UK Clinical Trials Unit. The Principal Biostatistician role places an emphasis on leading a programme of research and continuing to win grant funding for new trials. I continued to supervise trials launched in the Senior Biostatistician role, whilst adding a major trial in idiopathic intracranial hypertension. I designed and delivered a 40-hour programme of technical training for new Biostatisticians, and wrote an MSc module on early phase trials.
Promotion at the Cancer Research UK Clinical Trials Unit to lead biostatistical aspects in a brand new team devoted to early phase trials outside of cancer. The Senior Biostatistician role places a much greater emphasis on designing new trials, winning trial funding, and setting up trials. I served on trials in burns, trauma, amyotrophic lateral sclerosis, inflammatory bowel disease, and Wolfram Syndrome, whilst retaining some involvement in cancer trials.
As a clinical trial statistician at the Cancer Research UK Clinical Trials Unit, I worked on a range of early phase trials in lung cancer and haematological malignancies. The core responsibilities were to perform trial analyses, produce reports for publication and safety monitoring, and produce documentation in accordance with the trials unit's quality management processes.